Dr. SK Hozaifah, Founder & Chairman – ASH Group Enterprises Pvt. Ltd. एवं Chief Editor – ASH24 News, वरिष्ठ पत्रकार श्री Bindeshwar Prasad Gupta जी तथा HCL में कार्यरत श्री Kumar Anil जी के साथ बिहार विधान परिषद, पटना के सभागार में आयोजित पंडित राजकुमार शुक्ल स्मृति सम्मान–2026 समारोह के दौरान एक गरिमामयी एवं यादगार पल—सम्मान, संवाद और पत्रकारिता से जुड़ी यह तस्वीर सदैव स्मरणीय
September 1, 2026 at 10:27 PM
Dr. SK Hozaifah, Founder & Chairman – ASH Group Enterprises Pvt. Ltd. एवं Chief Editor – ASH24 News, वरिष्ठ पत्रकार श्री Bindeshwar Prasad Gupta जी तथा HCL में कार्यरत श्री Kumar Anil जी के साथ बिहार विधान परिषद, पटना के सभागार में आयोजित पंडित राजकुमार शुक्ल स्मृति सम्मान–2026 समारोह के दौरान एक गरिमामयी एवं यादगार पल—सम्मान, संवाद और पत्रकारिता से जुड़ी यह तस्वीर सदैव स्मरणीय
Dr. Olivier Elemento @wcmenglanderipm.bsky.social from CAP-IT CRI U54 at Weill Cornell Medicine chaired the session #ArtificialIntelligence in #hematology: from #GenerativeAI to ethics and applications” today at the #ASH24 Annual Meeting in San Diego.
#InvestigatorNews
#InvestigatorNews
December 13, 2024 at 1:49 AM
Dr. Olivier Elemento @wcmenglanderipm.bsky.social from CAP-IT CRI U54 at Weill Cornell Medicine chaired the session #ArtificialIntelligence in #hematology: from #GenerativeAI to ethics and applications” today at the #ASH24 Annual Meeting in San Diego.
#InvestigatorNews
#InvestigatorNews
New-to-blue but feared by myeloma and well-known to the myeloma world: @drmhb.bsky.social moderating #ASH24 myeloma treatment session
December 9, 2024 at 12:30 AM
New-to-blue but feared by myeloma and well-known to the myeloma world: @drmhb.bsky.social moderating #ASH24 myeloma treatment session
Let’s throw out the jugs!
@rahulbanerjeemd.bsky.social presents “24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702” #ASH24
@rahulbanerjeemd.bsky.social presents “24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702” #ASH24
December 7, 2024 at 5:59 PM
Let’s throw out the jugs!
@rahulbanerjeemd.bsky.social presents “24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702” #ASH24
@rahulbanerjeemd.bsky.social presents “24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702” #ASH24
Ugh hotel coffee before Day 2 of #ASH24
I’m a robotics parent too! My 15 is completely obsessed. On my between-conference-sessions-To-Do list is to books flights for a tournament in Canada!
I’m a robotics parent too! My 15 is completely obsessed. On my between-conference-sessions-To-Do list is to books flights for a tournament in Canada!
December 7, 2024 at 1:52 PM
Ugh hotel coffee before Day 2 of #ASH24
I’m a robotics parent too! My 15 is completely obsessed. On my between-conference-sessions-To-Do list is to books flights for a tournament in Canada!
I’m a robotics parent too! My 15 is completely obsessed. On my between-conference-sessions-To-Do list is to books flights for a tournament in Canada!
There are at least 4 synchronous industry-sponsored “women in hematology” events on Saturday night at #ASH24.
Makes you wonder who the event is really for?
Makes you wonder who the event is really for?
a black and white photo of a woman in a kitchen with a disney logo in the corner
ALT: a black and white photo of a woman in a kitchen with a disney logo in the corner
media.tenor.com
November 22, 2024 at 5:13 PM
There are at least 4 synchronous industry-sponsored “women in hematology” events on Saturday night at #ASH24.
Makes you wonder who the event is really for?
Makes you wonder who the event is really for?
Three clinical trials led by MD Anderson researchers yielded strong results in multiple leukemias.
Read more about the results, presented at #ASH24:
#Leukemia #EndCancer
Read more about the results, presented at #ASH24:
#Leukemia #EndCancer
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
SAN DIEGO ― Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of r...
www.mdanderson.org
December 10, 2024 at 1:21 AM
Three clinical trials led by MD Anderson researchers yielded strong results in multiple leukemias.
Read more about the results, presented at #ASH24:
#Leukemia #EndCancer
Read more about the results, presented at #ASH24:
#Leukemia #EndCancer
Our Dr. Abhishek Maiti presented data at #ASH24 from a Phase Ib trial that demonstrated a 100% response rate in patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis treated with a monoclonal antibody therapy.
Learn more: bit.ly/4f9992T #EndCancer
Learn more: bit.ly/4f9992T #EndCancer
ASH: Monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclon...
bit.ly
December 9, 2024 at 10:52 PM
Our Dr. Abhishek Maiti presented data at #ASH24 from a Phase Ib trial that demonstrated a 100% response rate in patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis treated with a monoclonal antibody therapy.
Learn more: bit.ly/4f9992T #EndCancer
Learn more: bit.ly/4f9992T #EndCancer
Our Dr. Uday Popat presented findings from a phase II trial at #ASH24 that examined the effectiveness of adding novel agents and lengthening the treatment timeline for patients with high-risk leukemia.
Read more about his research: bit.ly/4ikijfG #Leukemia #EndCancer
Read more about his research: bit.ly/4ikijfG #Leukemia #EndCancer
December 9, 2024 at 12:44 AM
Our Dr. Uday Popat presented findings from a phase II trial at #ASH24 that examined the effectiveness of adding novel agents and lengthening the treatment timeline for patients with high-risk leukemia.
Read more about his research: bit.ly/4ikijfG #Leukemia #EndCancer
Read more about his research: bit.ly/4ikijfG #Leukemia #EndCancer
Dr. Vera Adema presents on the therapeutic potential of targeting the HRI pathway to overcome anemia, reducing the need for blood transfusions in patients with MDS-RS and sickle cell disease at #ASH24.
Read more about her research: bit.ly/4ikijfG #EndCancer
Read more about her research: bit.ly/4ikijfG #EndCancer
December 7, 2024 at 9:13 PM
Dr. Vera Adema presents on the therapeutic potential of targeting the HRI pathway to overcome anemia, reducing the need for blood transfusions in patients with MDS-RS and sickle cell disease at #ASH24.
Read more about her research: bit.ly/4ikijfG #EndCancer
Read more about her research: bit.ly/4ikijfG #EndCancer
Our Dr. Alexandre Bazinet presents results from a phase II study examining the addition of cladribine to the standard of care treatment in patients newly diagnosed acute myeloid leukemia at #ASH24.
December 7, 2024 at 6:33 PM
Our Dr. Alexandre Bazinet presents results from a phase II study examining the addition of cladribine to the standard of care treatment in patients newly diagnosed acute myeloid leukemia at #ASH24.
At #ASH24, our experts will showcase their latest research with colleagues from across the globe for large-scale discussion.
Keep up with research highlights and presentation schedules here: bit.ly/41kMFIP @ash-hematology.bsky.social #EndCancer
Keep up with research highlights and presentation schedules here: bit.ly/41kMFIP @ash-hematology.bsky.social #EndCancer
MD Anderson at ASH
Keep up with the latest from MD Anderson experts presenting at ASH Annual Meeting and Exposition and learn more about our pioneering hematology research.
bit.ly
December 7, 2024 at 2:57 PM
At #ASH24, our experts will showcase their latest research with colleagues from across the globe for large-scale discussion.
Keep up with research highlights and presentation schedules here: bit.ly/41kMFIP @ash-hematology.bsky.social #EndCancer
Keep up with research highlights and presentation schedules here: bit.ly/41kMFIP @ash-hematology.bsky.social #EndCancer
The latest MD Anderson research in hematological malignancies and diseases will be presented at #ASH24, including novel treatments for MDS, leukemia and lymphoma and potential targets for overcoming anemia: brnw.ch/21wPcoY #EndCancer
MD Anderson Research Highlights: ASH 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless co...
brnw.ch
December 5, 2024 at 3:20 PM
The latest MD Anderson research in hematological malignancies and diseases will be presented at #ASH24, including novel treatments for MDS, leukemia and lymphoma and potential targets for overcoming anemia: brnw.ch/21wPcoY #EndCancer
Welcome to this OncoAlert Session Round Up during #ASH24, focusing on #MultipleMyeloma pharmacologic therapie
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
OncoAlert Session Round Up at ASH 24 in Multiple Myeloma: pharmacologic Therapies: Refining Evidence
Welcome to this OncoAlert Session Round Up during ASH24, focusing on Multiple Myeloma pharmacologic therapies.GMMG-HD7 Trial (JCO Publication)This phase 3 tr...
buff.ly
December 9, 2024 at 10:11 PM
Welcome to this OncoAlert Session Round Up during #ASH24, focusing on #MultipleMyeloma pharmacologic therapie
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
investigated efficacy of SC daratumumab, as a treatment for high-risk smoldering multiple myeloma, a precursor to active #MultipleMyeloma for which no approved treatments currently exist.
#ASH24
https://buff.ly/4fcbHgK
investigated efficacy of SC daratumumab, as a treatment for high-risk smoldering multiple myeloma, a precursor to active #MultipleMyeloma for which no approved treatments currently exist.
#ASH24
https://buff.ly/4fcbHgK
December 9, 2024 at 7:55 PM
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
investigated efficacy of SC daratumumab, as a treatment for high-risk smoldering multiple myeloma, a precursor to active #MultipleMyeloma for which no approved treatments currently exist.
#ASH24
https://buff.ly/4fcbHgK
investigated efficacy of SC daratumumab, as a treatment for high-risk smoldering multiple myeloma, a precursor to active #MultipleMyeloma for which no approved treatments currently exist.
#ASH24
https://buff.ly/4fcbHgK
JUST OUT #ASH24
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
December 9, 2024 at 7:17 PM
JUST OUT #ASH24
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
Welcome to this OncoAlert Session Round Up during #ASH24
Todays Round up is on Multiple Myeloma focusing on Advancing Minimal Residual Disease or MRD, on detection, impact on prognosis and treatment decisions
Transcript found on YouTube link
Todays Round up is on Multiple Myeloma focusing on Advancing Minimal Residual Disease or MRD, on detection, impact on prognosis and treatment decisions
Transcript found on YouTube link
OncoAlert Session Round Up at #ASH24 in Multiple Myeloma: Advancing Minimal Residual Disease (MRD)
Welcome to this OncoAlert Session Round Up during ASH24Todays ROund up is on Multiple Myeloma focusing on Advancing Minimal Residual Disease or MRD, on detec...
buff.ly
December 8, 2024 at 3:39 AM
Welcome to this OncoAlert Session Round Up during #ASH24
Todays Round up is on Multiple Myeloma focusing on Advancing Minimal Residual Disease or MRD, on detection, impact on prognosis and treatment decisions
Transcript found on YouTube link
Todays Round up is on Multiple Myeloma focusing on Advancing Minimal Residual Disease or MRD, on detection, impact on prognosis and treatment decisions
Transcript found on YouTube link
Ready for #ASH24
See you in San Diego @ash-hematology.bsky.social 🌞
Dec 7-10, 2024
@lymphomadoc.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@realbowtiedoc.bsky.social
@fernandoonco.bsky.social
@barbaramelao.bsky.social
@b-avalos-md.bsky.social
See you in San Diego @ash-hematology.bsky.social 🌞
Dec 7-10, 2024
@lymphomadoc.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@realbowtiedoc.bsky.social
@fernandoonco.bsky.social
@barbaramelao.bsky.social
@b-avalos-md.bsky.social
December 4, 2024 at 10:15 PM
🙏 🙏 Honored to have the work from @tjflemin.bsky.social from our lab featured in the Best of #ASH24!!!
Huge congratulations to both @tjflemin.bsky.social and @bloodgenes.bsky.social! Both Outstanding Abstract Achievement Award and Best of ASH! #ASH24 #ASHKudos @ash-hematology.bsky.social
December 11, 2024 at 12:28 AM
🙏 🙏 Honored to have the work from @tjflemin.bsky.social from our lab featured in the Best of #ASH24!!!
Outstanding presentation at #ASH24 from @tjflemin.bsky.social from our lab, where he discussed his work on the mechanisms by which MECOM drives high-risk AMLs!!! Congratulations, Travis!!!
December 10, 2024 at 1:54 AM
Outstanding presentation at #ASH24 from @tjflemin.bsky.social from our lab, where he discussed his work on the mechanisms by which MECOM drives high-risk AMLs!!! Congratulations, Travis!!!
One of my favorite parts of the @ash-hematology.bsky.social #ASH24 annual meeting is seeing many of the incredible people from around the world I am fortunate to work with, such as Samuele Ferrari from Milan, Italy and Siana Nkya from Tanzania! 🩸🩸🤝
December 10, 2024 at 12:43 AM
One of my favorite parts of the @ash-hematology.bsky.social #ASH24 annual meeting is seeing many of the incredible people from around the world I am fortunate to work with, such as Samuele Ferrari from Milan, Italy and Siana Nkya from Tanzania! 🩸🩸🤝
Please come see @tjflemin.bsky.social present on his groundbreaking work at @ash-hematology.bsky.social #ASH24 that reveals a surprisingly simple regulatory logic for high-risk AMLs ... Happening soon in Manchester Grand Hyatt San Diego Seaport Ballrooms ABCD:
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
Paper: Targeted Protein Degradation Reveals a Repressive Role of Mecom at the <em>CEBPA</Em> Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia
ash.confex.com
December 9, 2024 at 11:06 PM
Please come see @tjflemin.bsky.social present on his groundbreaking work at @ash-hematology.bsky.social #ASH24 that reveals a surprisingly simple regulatory logic for high-risk AMLs ... Happening soon in Manchester Grand Hyatt San Diego Seaport Ballrooms ABCD:
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...